Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/21/25
End: 08/30/27
Due: 08/30/28
Phase: N/A
Priority: Normal
Start: 10/11/24
End: 02/28/27
Due: 02/28/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | NCT06799065 | Accent Therapeutics | user2@example.com | None | 2025-03-21 | 2027-08-30 | 2028-08-30 | - | - | 2025-07-14 |
| First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | NCT06625515 | Accent Therapeutics | user2@example.com | None | 2024-10-11 | 2027-02-28 | 2028-02-28 | - | - | 2025-07-14 |